Furoscix in Practice: Selection, Delivery, Monitoring

Craig Beavers orients listeners to what Furoscix is and how it differs from oral and IV furosemide. Structurally, it is the furosemide clinicians already know, but pH-neutralized to permit subcutaneous administration. He describes the delivery mechanism: an 80 mg vial in a pre-programmed on-body infuser that attaches to the patient—typically on the abdomen—delivering 30 mg over the first hour and roughly 12.5 mg per hour across the next four, for a 5-hour total, after which the device is removed and discarded. Bypassing the GI tract provides the high bioavailability needed to reach the diuretic threshold in heart failure, chronic kidney disease, or both. On patient selection, Beavers describes several overlapping criteria: patients inadequately diuresed or showing congestion despite oral therapy, transitions-of-care patients discharged earlier than ideal who still need IV-level diuresis, and patients decompensating again after adequate diuresis. He also cites settings without a diuretic clinic and works with skilled nursing facilities. For monitoring, he tracks weights as the primary barometer, urine output, and periodic labs—sodium, potassium, BUN, and creatinine—noting the safety profile mirrors conventional furosemide without dramatic electrolyte shifts.